Authors
Latest:
Metastatic Colorectal Cancer: Ongoing Challenges and Future Directions in CareClosing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.
Latest:
Updated Safety and Efficacy Data From the Phase 3 MANIFEST-2 Study of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients With MyelofibrosisThis is safety and efficacy update on the MANIFEST-2 trial (NCT02158858), a global, randomized, double-blind, active-control, phase 3 study using pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.
Latest:
Peter B. Bach, MD, Discusses New Payment Reform ModelsPeter B. Bach, MD, MAPP, discussed at a conference recently hosted by The American Journal of Managed Care how new payment models are challenging the current fee-for-service model for community care cancer centers.
Latest:
Dr. Minna on Chemotherapy and Radiation Therapy for Lung CancerJohn Minna, MD, Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology, Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research, Hamon Center for Therapeutic Oncology, Internal Medicine, Pharmacology, UT Southwestern Medical Center, discusses the roles that both chemotherapy and radiation therapy will continue to have in the treatment of lung cancer.
Latest:
Dr. Morris on Lymphopenia as a Predictor of Survival in CRT-Treated NSCLCJohn Morris, MD, professor of Medicine, co-director, Comprehensive Lung Cancer Center, associate director, UCCI Translational Research and Director, Experimental Therapeutics, University of Cincinnatti, discusses lymphopenia as a predictor of survival in chemoradiation-treated non–small cell lung cancer.
Latest:
Dr Mascarenhas on First-line Treatment Decisions in MyelofibrosisJohn Mascarenhas, MD, discusses first-line treatment decisions for patients with myelofibrosis.
Latest:
Biomarkers in Ovarian Cancer: Early Detection and ChemoresistanceWorldwide, there are ~204,000 new cases of ovarian cancer each year, accounting for 4% of cancers diagnosed in women.
Latest:
Second-Line Therapies for mCRPC Complicated by Drug Interactions and Dosing IssuesApproximately 4 years after the FDA approval of 2 powerful new oral androgen-targeting agents for metastatic castration-resistant prostate cancer, an analysis raised issues complicating treatment with the 2 drugs, as well as what oncologists do not yet know.
Latest:
Exploring Emerging Data in DLBCLA panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.
Latest:
Novel Protein May Provide Tool to Target Elusive RAS OncogeneGiven the "addiction" of many tumors to mutant RAS for their survival, there has been renewed interest in developing new ways to inhibit RAS in cancer.
Latest:
Dr. Sfakianos on the Utility of Adjuvant Therapy in Bladder Cancer ManagementJohn P. Sfakianos, MD, discusses the utility of adjuvant therapy in bladder cancer management.
Latest:
Dr. Primrose on Adjuvant Capecitabine For Biliary Tract CancerJohn Primrose, MD, ChB, FRCS, professor of medicine/surgery, University of Southampton, United Kingdom, discusses the impact of adjuvant capecitabine in patients with biliary tract cancer.
Latest:
Drug Interactions With Tyrosine Kinase InhibitorsTyrosine Kinase Inhibitors (TKIs) are indicated for the treatment of a variety of malignancies, due to their ability to interfere with cell communication and growth. This review focuses on interactions that affect TKI metabolism.
Latest:
The Importance of Mentoring in Preparing the Next Generation of OncologistsSince the time of Hippocrates, practicing the art of medicine has involved the passage of knowledge and experience from one generation of practitioners to the next.
Latest:
Dr. Robertson on Subgroup Analysis of the FALCON Trial for HR+ Breast CancerJohn Robertson, MD, professor of Surgery, University of Nottingham, Royal Derby Hospital Centre, United Kingdom, discusses a subgroup analysis of the FALCON trial, which compared treatment with fulvestrant (Faslodex) versus anastrozole (Arimidex) in patients with HR-positive advanced breast cancer.
Latest:
Patient-Derived Cancer Stem Cells Offer Diagnostic and Therapeutic Potential in Brain CancerA brain tumor research group at the UW Carbone Cancer Center focuses on biological studies of patient-derived glioblastoma multiforme (GBM) cancer stem cells, combined with analysis of patient-matched serum-cultured GBM and an annotated GBM tissue microarray, to identify clinically relevant biomarkers.
Latest:
Dr Strickler on the Role of Biomarker Testing in Pancreatic CancerJohn H. Strickler, MD, discusses the role of biomarker testing in metastatic pancreatic cancer.
Latest:
Dr. Sweetenham on Unanswered Questions With CAR T-Cell Therapy in Pediatric ALLJohn Sweetenham, MD, associate director for clinical affairs, Harold G. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses unanswered questions with CAR T-cell therapy in pediatric acute lymphoblastic leukemia.
Latest:
Dr. Comerci on the Use of Laparoscopy in Ovarian CancerJohn T. Comerci, MD, associate professor, University of Pittsburgh School of Medicine, and director of Gynecologic Oncology, University of Pittsburgh Medical Center Passavant Hospital, discusses the use of laparoscopy in ovarian cancer.
Latest:
Dr. Heymach on the Efficacy of Mobocertinib in EGFR Exon 20 Insertion–Mutated NSCLCJohn V. Heymach, MD, PhD, discusses the efficacy of mobocertinib in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.
Latest:
Second-Line Treatment of SCLCVamsidhar Velcheti, MD, leads the discussion on the current standard of care and approaching the treatment of second-line SCLC.
